Novo Nordisk Reports Strong Revenue Growth Amid R&D Progress

Novo Nordisk experienced a remarkable 26% sales growth in 2024, driven by its diabetes and obesity treatments. The company maintains a positive outlook for 2025, promising continued exploration of innovative treatment solutions.

Date: 05-02-2025

AI Rating: 7

Earnings Per Share (EPS)
In 2024, Novo Nordisk reported a diluted EPS increase of 22% to DKK 22.63, influenced by impairment losses related to intangible assets.

Revenue Growth
The company achieved significant sales growth of 26% at constant exchange rates, primarily fueled by its GLP-1 portfolio and substantial performance across both North American and international operations. The North America division alone saw a sales increase of 30%.

Net Income
Net profit rose by 21% year-over-year, signifying robust profitability alongside increased sales figures.

Profit Margins
The gross margin improved slightly to 84.7%, aided by favorable pricing impacts, contributing positively to profitability despite costs associated with capacity expansions.

Free Cash Flow (FCF)
The free cash flow stood at minus DKK 14.7 billion, compared to a positive DKK 68.3 billion in 2023, primarily impacted by substantial capital expenditures related to supply chain expansions and acquisitions.

Return on Equity (ROE)
The report does not specifically mention the Return on Equity, making it unclear how initially reported profits translate into shareholder equity returns.

Stocks: NVO